Literature DB >> 18804937

Immediate endovascular repair for acute traumatic injuries of the thoracic aorta: a multicenter analysis of 28 cases.

Jean-Marc Alsac1, Benoit Boura, Pascal Desgranges, Jean-Noël Fabiani, Jean-Pierre Becquemin, Guy Leseche.   

Abstract

OBJECTIVE: Endovascular repair of injured thoracic aorta offers a new minimal invasive therapeutic option that could be beneficial in the urgent management of polytrauma patients. The aim of this study was to assess our multicenter experience of immediate endovascular repair for acute traumatic injuries of the thoracic aorta.
METHODS: Between April 2002 and October 2007, all patients treated for an acute traumatic injury of the thoracic aorta, in a less than 12-hour delay, by endovascular repair, were reviewed retrospectively in three Parisian trauma centers. Collected data included age, sex, associated comorbidities, and traumatic lesions to determine the Traumatic Injury Severity Score (TRISS), the type of aortic lesion assessed by computed tomography (CT)-scan and transesophageal ultrasonography, technical aspects of endovascular repair, length of hospital stay, and postoperative mortality. Patients were regularly followed by clinical examination, chest radiographs, and thoracic CT-scan.
RESULTS: Twenty-eight patients (20 males, mean age 45 +/- 18.8 years) were treated in a median delay of 5 hours (range 2 to 10 hours) after initial trauma. They all experienced severe traumatic injuries with a mean predictive mortality of 55.6% +/- 33.1% according to TRISS. Aortic lesions were associated with aortic parietal hematoma (71%), hemomediastinum (86%), and hemothorax (68%). All endovascular procedures were technically successful through femoral (n = 24) or iliac access (n = 4), in a mean operating time of 94 +/- 35.8 minutes. Proximal sealing of the endografts required the coverage of the origin of the left subclavian artery in 13 cases and of the left common carotid in one case. The median of hospital stay was 27 days (range 9 to 127 days), with an overall hospital mortality of 17.9% (n = 5). All deaths were unrelated to the aortic rupture or the stent placement, and no intervention-related morbidity or mortality was recorded during a median follow-up of 24 months (range 5 to 73 months).
CONCLUSION: Endovascular stent grafting allows an immediate efficient repair for acute traumatic injuries of the thoracic aorta. This early management is, however, associated with a high in-hospital mortality, related to the severe concomitant injuries of such unselected multitrauma patients.

Entities:  

Mesh:

Year:  2008        PMID: 18804937     DOI: 10.1016/j.jvs.2008.07.019

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Case Report: En Bloc Resection of Pancoast Tumor with Adjuvant Aortic Endograft and Chemoradiation.

Authors:  Tony Lu; Uwe M Fischer; Rex A Marco; Joseph J Naoum; Michael J Reardon; Alan B Lumsden; Shanda H Blackmon; Mark G Davies
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Apr-Jun

2.  Endovascular and open repair for blunt aortic injury, treated in one clinical institution in Brazil: a case series.

Authors:  Igor Rafael Sincos; Ricardo Aun; Sergio Quilici Belczak; Luciano Dias Nascimento; Boulanger Mioto Netto; Ivan Casella; Erasmo Simao da Silva; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

3.  The Importance of the Mediastinal Triangle in Traumatic Lesions of the Aorta.

Authors:  Daniel Gulias-Soidan; Daniel Fraga-Manteiga; Víctor X Mosquera-Rodriguez; Milagros Marini-Diaz; Paula Lopez-Bargiela; Cristina González-Martín; Vanesa Balboa-Barreiro
Journal:  Medicina (Kaunas)       Date:  2019-06-10       Impact factor: 2.430

4.  Endovascular Repair of Thoracic Aorta Injury: 17 Years of Single-Center Experience.

Authors:  Václav Procházka; Jan Roman; František Jalůvka; Tomáš Jonszta; Adéla Vrtková; Leopold Pleva; Vladimír Ječmínek; Jiří Sieja; Radim Brát
Journal:  Med Sci Monit       Date:  2021-11-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.